

Mirati Therapeutics Investor Relations Department 9393 Towne Centre Drive Suite 200 Tel.: 858.332.3410 San Diego, CA 92121 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: MRTX	
Last Trade:	4.95
Trade Time:	4:00 PM ET Jul 24, 2017
Change:	0.05 🕈 (+1.020%)
Day Range	4.65 - 5.05
52-Week Range	2.70 - 7.22
Volume	155,021


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Mirati Therapeutics is a targeted oncology company developing therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications. Mirati trades on the NASDAQ under the ticker symbol "MRTX."

... (more)

Stock Performance



Press Releases [View all]

Jul 5, 2017

Mirati Therapeutics To Host Key Opinion
Leader Breakfast On Immuno-oncology
Combinations On July 11 In New York

Jun 27, 2017

Mirati Therapeutics Announces Appointment
Of Neil Reisman To The Board Of Directors

May 31, 2017

Mirati Therapeutics To Present At The 2017

Jefferies Global Healthcare Conference

May 4, 2017

Mirati Therapeutics Reports First Quarter 2017 Financial Results

Mar 9, 2017

Mirati Therapeutics Reports Financial Results
And Provides Business Update For The
Fourth Quarter And Full Year 2016

Financials [View all]

First Quarter Financial Results

Mar 9, 2017

Annual Report (10-K)

Apr 20, 2017

Proxy Statement (DEF 14A)

May 4, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)

Aug 4, 2016

Quarterly Report (10-Q)